| scholarly article | Q13442814 |
| P50 | author | Louis-Philippe Boulet | Q61053270 |
| Barbro Dahlén | Q114399083 | ||
| P2093 | author name string | John G Matthews | |
| Lawren C Wu | |||
| Richard Leigh | |||
| J Mark Fitzgerald | |||
| Heleen Scheerens | |||
| Donald W Cockcroft | |||
| Paul M O'Byrne | |||
| Gail M Gauvreau | |||
| Irvin Mayers | |||
| X Charlene Liao | |||
| Wendy S Putnam | |||
| Yanan Zheng | |||
| Beth E Davis | |||
| Romeo Maciuca | |||
| Yehong Wang | |||
| Jeffrey M Harris | |||
| P2860 | cites work | Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice | Q24604440 |
| Clinical phenotypes of asthma | Q28166988 | ||
| Inhibition of IgE synthesis by anti-IgE: role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE. | Q33559272 | ||
| Asthma, allergy, and IgE levels in NYC head start children. | Q33678650 | ||
| Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells. | Q34093487 | ||
| The biology of IGE and the basis of allergic disease | Q34167019 | ||
| IgE regulation and roles in asthma pathogenesis | Q34176252 | ||
| Targeting the extracellular membrane-proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo | Q34222417 | ||
| Migration of antibody secreting cells towards CXCL12 depends on the isotype that forms the BCR. | Q34259851 | ||
| Seasonal changes in IgE antibodies and their relationship to IgG antibodies during immunotherapy for ragweed hay fever | Q34504566 | ||
| Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. | Q35183644 | ||
| Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma | Q35574100 | ||
| Allergen-specific IgE as a biomarker of exposure plus sensitization in inner-city adolescents with asthma | Q35936386 | ||
| Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey | Q36535792 | ||
| Asthma: defining of the persistent adult phenotypes | Q36578781 | ||
| The development of allergic inflammation | Q36613696 | ||
| A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. | Q36643902 | ||
| Effect of environmental allergen sensitization on asthma morbidity in inner-city asthmatic children | Q36672280 | ||
| IgE in allergy and asthma today | Q37095248 | ||
| The distinctive germinal center phase of IgE+ B lymphocytes limits their contribution to the classical memory response | Q37322165 | ||
| Cluster analysis and clinical asthma phenotypes. | Q37711387 | ||
| Staying alive: regulation of plasma cell survival. | Q37946101 | ||
| The who, where, and when of IgE in allergic airway disease. | Q37968359 | ||
| IgE and mast cells in allergic disease | Q38007829 | ||
| What do we know about asthma triggers? a review of the literature | Q38097930 | ||
| The relationship between a specific IgE level and asthma outcomes: results from the 2005-2006 National Health and Nutrition Examination Survey | Q38880602 | ||
| Late asthmatic responses | Q39596924 | ||
| Lack of association between indoor allergen sensitization and asthma morbidity in inner-city adults | Q39798773 | ||
| Characterization of the human immunoglobulin epsilon mRNAs and their polyadenylation sites | Q40396916 | ||
| Characterization of four novel epsilon chain mRNA and a comparative analysis of genes for immunoglobulin E in rodents and man. | Q41581865 | ||
| Two unusual forms of human immunoglobulin E encoded by alternative RNA splicing of epsilon heavy chain membrane exons | Q42768980 | ||
| Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma | Q43701894 | ||
| The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics | Q43723871 | ||
| Transfer of atopy following bone marrow transplantation. | Q44798106 | ||
| Fluorescent in vivo detection reveals that IgE(+) B cells are restrained by an intrinsic cell fate predisposition. | Q45671838 | ||
| IgE antibody quantification and the probability of wheeze in preschool children | Q47715148 | ||
| IgE⁺ memory B cells and plasma cells generated through a germinal-center pathway. | Q50501770 | ||
| Long-lived IgE- and IgG-secreting cells in rodents manifesting persistent antibody responses. | Q52209058 | ||
| Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge. | Q52907994 | ||
| P433 | issue | 243 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 243ra85 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production | |
| P478 | volume | 6 |
| Q37625474 | A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help |
| Q36700648 | A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma |
| Q35289292 | A single glycan on IgE is indispensable for initiation of anaphylaxis. |
| Q47146658 | An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases. |
| Q47551081 | Anti-IL5 therapies for asthma. |
| Q90353156 | Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells |
| Q38351475 | Anti-interleukin therapy in asthma |
| Q38528048 | Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies |
| Q38579923 | Asthma treatments: new and emerging therapies |
| Q37660379 | CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. |
| Q90317508 | Cell-bound IgE and plasma IgE as a combined clinical diagnostic indicator for allergic patients |
| Q89491066 | Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis |
| Q38751342 | Current and future therapies for treating chronic spontaneous urticaria |
| Q39108259 | Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies |
| Q36870059 | Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. |
| Q38394577 | EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders |
| Q38344266 | Emerging biologics for the treatment of chronic rhinosinusitis |
| Q39434071 | Endotype-driven treatment in chronic upper airway diseases. |
| Q38571093 | IgE receptor signaling in food allergy pathogenesis. |
| Q36933639 | Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates |
| Q41633977 | Innovative treatments for severe refractory asthma: how to choose the right option for the right patient? |
| Q24186306 | Mepolizumab versus placebo for asthma |
| Q51687473 | Monoclonal Antibodies for the Management of Severe Asthma. |
| Q47873103 | New approaches for identifying and testing potential new anti-asthma agents. |
| Q38950769 | Novel Biologicals for the Treatment of Allergic Diseases and Asthma |
| Q28073074 | Personalized Medicine in Allergy |
| Q55097573 | Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps. |
| Q93061181 | Protective Effect of Circular RNA (CircRNA) Ddx17 in Ovalbumin (OVA)-Induced Allergic Rhinitis (AR) Mice |
| Q104284044 | Regulation of the humoral type 2 immune response against allergens and helminths |
| Q36340310 | Specific immunotherapy in combination with Clostridium butyricum inhibits allergic inflammation in the mouse intestine |
| Q38588854 | Targeting the interleukin pathway in the treatment of asthma |
| Q30276742 | The Developmental History of IgE and IgG4 Antibodies in Relation to Atopy, Eosinophilic Esophagitis, and the Modified TH2 Response |
| Q38348057 | The future of biologics: applications for food allergy |
| Q38843261 | The path to personalized medicine in asthma. |
| Q92988172 | Tracing IgE-Producing Cells in Allergic Patients |
| Q38811111 | Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody |
| Q57166694 | [Immunology of chronic rhinosinusitis with nasal polyps as a basis for treatment with biologicals] |
Search more.